{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:00:52Z","timestamp":1791820852867,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.anai.2026.05.034","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:36:27Z","timestamp":1780155387000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal antibodies targeting inflammatory pathways in chronic obstructive pulmonary disease"],"prefix":"10.1016","author":[{"given":"Bryan A.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Jeskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-6886","authenticated-orcid":false,"given":"Simon","family":"Couillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0001","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/SPC.0000000000000377","article-title":"Pathophysiological mechanisms of exertional breathlessness in chronic obstructive pulmonary disease and interstitial lung disease","volume":"12","author":"Jensen","year":"2018","journal-title":"Curr Opin Support Palliat Care"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0002","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0003","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.05.034_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/COPD.S285338","article-title":"The prevalence of chronic obstructive pulmonary disease (COPD) and the heterogeneity of risk factors in the Canadian population: results from the Canadian Obstructive Lung Disease (COLD) study","volume":"16","author":"Leung","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9859","key":"10.1016\/j.anai.2026.05.034_bib0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2026.05.034_bib0006","unstructured":"Canadian Institute for Health Information. Hospital Stays in Canada (2022\u20132023). Canadian Institute for Health Information; 2024. Accessed June 1, 2026. https:\/\/www.cihi.ca\/en\/hospital-stays-in-canada-2023-2024"},{"key":"10.1016\/j.anai.2026.05.034_bib0007","unstructured":"GOLD. Global Strategy for the Diagnosis, Management, and Prevention of COPD; 2026. Accessed June 1, 2026. https:\/\/goldcopd.org\/"},{"issue":"8","key":"10.1016\/j.anai.2026.05.034_bib0008","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S2213-2600(25)00215-2","article-title":"Breathing barriers: bridging lung health, research, and awareness","volume":"13","author":"Pott","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2026.05.034_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00516-2024","article-title":"20-year trends in excess costs of COPD","volume":"65","author":"Amegadzie","year":"2025","journal-title":"Eur Respir J"},{"issue":"35","key":"10.1016\/j.anai.2026.05.034_bib0011","doi-asserted-by":"crossref","first-page":"E1172","DOI":"10.1503\/cmaj.221051","article-title":"Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada","volume":"195","author":"Amegadzie","year":"2023","journal-title":"CMAJ"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0012","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","article-title":"An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome Proposal","volume":"204","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2026.05.034_bib0013","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2026.05.034_bib0014","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chest.2016.10.003","article-title":"Eosinophils in COPD exacerbations are associated with increased readmissions","volume":"151","author":"Couillard","year":"2017","journal-title":"Chest"},{"issue":"5 Pt 1","key":"10.1016\/j.anai.2026.05.034_bib0015","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"9589","key":"10.1016\/j.anai.2026.05.034_bib0016","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.anai.2026.05.034_bib0017","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.05.034_bib0018","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2147\/COPD.S322036","article-title":"COPD exacerbation history and impact on future exacerbations \u22128-year retrospective observational database cohort study from Germany","volume":"16","author":"Vogelmeier","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0019","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/15412555.2017.1343814","article-title":"Predicting one-year mortality after a \u201cfirst\u201d hospitalization for chronic obstructive pulmonary disease: an eight-variable assessment score tool","volume":"14","author":"Vanasse","year":"2017","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13561-021-00329-9","article-title":"Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review","volume":"11","author":"Guti\u00e9rrez Villegas","year":"2021","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.anai.2026.05.034_bib0022","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/COPD.S350248","article-title":"Relationship of COPD exacerbation severity and frequency on risks for future events and economic burden in the Medicare fee-for-service population","volume":"17","author":"Sethi","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.anai.2026.05.034_bib0023","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.11.15003","article-title":"Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade","volume":"11","author":"Adeloye","year":"2021","journal-title":"J Glob Health"},{"issue":"6077","key":"10.1016\/j.anai.2026.05.034_bib0024","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/bmj.1.6077.1645","article-title":"The natural history of chronic airflow obstruction","volume":"1","author":"Fletcher","year":"1977","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.anai.2026.05.034_bib0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.93.04040479","article-title":"The Dutch hypothesis (chronic non-specific lung disease) revisited","volume":"4","author":"Sluiter","year":"1991","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2026.05.034_bib0026","doi-asserted-by":"crossref","unstructured":"O'Neal W., Schworer SA., Lee JA. Overlapping Mechanisms and Novel Biomarkers Define Asthma and COPD as a Spectrum of Airway Disease. Ann Allergy Asthma Immunol. 2026; In Press.","DOI":"10.1016\/j.anai.2026.06.022"},{"issue":"9","key":"10.1016\/j.anai.2026.05.034_bib0027","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.rmed.2012.11.008","article-title":"Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease","volume":"107","author":"Rennard","year":"2013","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0029","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1378\/chest.126.3.926","article-title":"Efficacy and safety of a monoclonal antibody recognizing interleukin-8 COPD: a pilot study","volume":"126","author":"Mahler","year":"2004","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0030","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A randomized, placebo-controlled Phase 2 trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0032","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0033","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02486-2016","article-title":"A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis","volume":"49","author":"Dasgupta","year":"2017","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.anai.2026.05.034_bib0034","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.anai.2026.05.034_bib0035","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2026.05.034_bib0036","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500012","article-title":"Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization","volume":"4","author":"Flynn","year":"2025","journal-title":"NEJM Evid"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0037","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0038","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0039","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.anai.2026.05.034_bib0040","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0041","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0042","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0043","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh","year":"2025","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0044","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.05.034_bib0045","doi-asserted-by":"crossref","unstructured":"Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921-972.","DOI":"10.1016\/S0140-6736(22)01273-9"},{"issue":"2","key":"10.1016\/j.anai.2026.05.034_bib0046","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00563-2019","article-title":"Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD","volume":"55","author":"Osei","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0047","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1172\/JCI121087","article-title":"An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup","volume":"129","author":"Christenson","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.anai.2026.05.034_bib0048","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thoraxjnl-2012-202432","article-title":"TNF\u03b1 antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial","volume":"68","author":"Aaron","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2026.05.034_bib0049","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/ajrccm.163.2.2003122","article-title":"Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease","volume":"163","author":"Aaron","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.05.034_bib0050","series-title":"Janeway\u2019s Immunobiology","author":"Murphy","year":"2022"},{"issue":"10","key":"10.1016\/j.anai.2026.05.034_bib0051","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/biomedicines9101312","article-title":"Inhaled corticosteroids and the lung microbiome in COPD","volume":"9","author":"Keir","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.anai.2026.05.034_bib0052","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00451-2017","article-title":"Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD","volume":"50","author":"Contoli","year":"2017","journal-title":"Eur Respir J"},{"issue":"507","key":"10.1016\/j.anai.2026.05.034_bib0053","doi-asserted-by":"crossref","first-page":"eaav3879","DOI":"10.1126\/scitranslmed.aav3879","article-title":"Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease","volume":"11","author":"Singanayagam","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10118","key":"10.1016\/j.anai.2026.05.034_bib0054","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2026.05.034_bib0056","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.immuni.2017.11.015","article-title":"Recent advances in type-2-cell-mediated immunity: insights from helminth Infection","volume":"47","author":"Harris","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0057","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00063198-199901000-00003","article-title":"Immune dysregulation as a cause for allergic asthma","volume":"5","author":"Lipscomb","year":"1999","journal-title":"Curr Opin Pulm Med"},{"issue":"11","key":"10.1016\/j.anai.2026.05.034_bib0058","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2026.05.034_bib0059","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thoraxjnl-2020-214644","article-title":"Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease","volume":"77","author":"Annangi","year":"2022","journal-title":"Thorax"},{"issue":"10388","key":"10.1016\/j.anai.2026.05.034_bib0060","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(23)00556-1","article-title":"The Lancet COPD Commission: broader questions remain","volume":"401","author":"Petousi","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2026.05.034_bib0061","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.15609","article-title":"Sounding the alarmins-The role of alarmin cytokines in asthma","volume":"78","author":"Gauvreau","year":"2023","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0062","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaci.2025.11.014","article-title":"High airway thymic stromal lymphopoietin in asthma is associated with type 2 inflammation, mucus plugging, and airway remodeling","volume":"157","author":"Khanna","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.05.034_bib0063","doi-asserted-by":"crossref","unstructured":"Pathak C., Cox J., Suri R., Akuthota P. Biomarkers for COPD with Type 2 Inflammation. Ann Allergy Asthma Immunol. 2026; In Press.","DOI":"10.1016\/j.anai.2026.06.035"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0064","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2026.05.034_bib0065","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03823-2020","article-title":"Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study","volume":"58","author":"Park","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2026.05.034_bib0066","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/thorax-2023-220972","article-title":"Type 2 inflammation and lung function decline in chronic airway disease in the general population","volume":"79","author":"Colak","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2026.05.034_bib0067","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/COPD.S187375","article-title":"Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths","volume":"14","author":"Li","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.anai.2026.05.034_bib0068","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.2147\/COPD.S170743","article-title":"Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization","volume":"13","author":"B\u00e9langer","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.anai.2026.05.034_bib0069","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/thoraxjnl-2015-207775","article-title":"Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD","volume":"71","author":"Echevarria","year":"2016","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.anai.2026.05.034_bib0070","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/all.16146","article-title":"The effects of inhaled corticosteroids on healthy airways","volume":"79","author":"Marchi","year":"2024","journal-title":"Allergy"},{"issue":"15","key":"10.1016\/j.anai.2026.05.034_bib0071","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJM195110112451501","article-title":"Clinical studies on the activity of orally administered cortisone","volume":"245","author":"Thorn","year":"1951","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0072","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.anai.2026.05.034_bib0073","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/thx.2006.073429","article-title":"Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma","volume":"62","author":"Berry","year":"2007","journal-title":"Thorax"},{"issue":"9171","key":"10.1016\/j.anai.2026.05.034_bib0074","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S2213-2600(23)00298-9","article-title":"Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial","volume":"12","author":"Ramakrishnan","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.anai.2026.05.034_bib0076","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","article-title":"Eosinophils in COPD: just another biomarker?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.anai.2026.05.034_bib0077","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/thorax-2025-223459","article-title":"Smoking gun: when COPD therapies fail current smokers","volume":"80","author":"Ben Hamou-Kuijpers","year":"2025","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0078","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.rmed.2011.11.003","article-title":"The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications","volume":"106","author":"Tamimi","year":"2012","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0079","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000117386","article-title":"Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study","volume":"76","author":"Dentener","year":"2008","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.anai.2026.05.034_bib0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","article-title":"First study of infliximab treatment in patients with chronic obstructive pulmonary disease","volume":"172","author":"van der Vaart","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.anai.2026.05.034_bib0081","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen general population study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0082","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00838-2020","article-title":"High eosinophil counts predict decline in FEV1: results from the CanCOLD study","volume":"57","author":"Tan","year":"2021","journal-title":"Eur Respir J"},{"issue":"14","key":"10.1016\/j.anai.2026.05.034_bib0083","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0084","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/Glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.anai.2026.05.034_bib0085","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0086","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0087","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with Benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.05.034_bib0088","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.chest.2024.09.049","article-title":"The emerging role of alarmin-targeting biologics in the treatment of patients with COPD","volume":"167","author":"Celli","year":"2025","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.anai.2026.05.034_bib0089","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.05.034_bib0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2022","article-title":"Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE\/EGFR signalling complex","volume":"62","author":"Strickson","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.05.034_bib0091","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.anai.2026.05.034_bib0092","doi-asserted-by":"crossref","unstructured":"Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, et al. Safety and efficacy of Astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, Phase 2b and 3 Trials. Lancet; 2026;407(10543):2027-2039.","DOI":"10.1016\/S0140-6736(26)00637-9"},{"issue":"suppl 1","key":"10.1016\/j.anai.2026.05.034_bib0093","article-title":"A34-01 relation between airway damage and disease activity and the effect of dupilumab on exacerbations and lung function in chronic obstructive pulmonary disease: BOREAS and NOTUS","volume":"212","author":"Couillard","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2026.05.034_bib0094","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:58:16Z","timestamp":1785974296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626002395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":93,"alternative-id":["S1081120626002395"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.05.034","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies targeting inflammatory pathways in chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}